Date: 2012-10-30
Type of information: Grant
Company: Complix (Belgium)
Investors: Flemish agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: € 1.9 Million
Funding type: grant
Planned used: The grant will allow Complix to accelerate the development of its unique cell penetrating Alphabodies (CPABs), against a range of intracellular disease targets, including cancer. Alphabodies represent a novel therapeutic development platform with the potential to address a vast number of disease targets that are currently considered
Others: Complix has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).Complix discovers and develops Alphabodies. These Alphabodies are small single chain alpha-helical proteins that are designed by computer modeling, but are inspired by naturally existing polypeptide structures. Alphabodies can address a diverse range of traditionally undruggable disease targets and combine the best beneficial properties of biologics and small chemical drugs, such as high specificity and potency on large protein targets, with efficient intracellular penetration and excellent stability in human serum.
Complix is also developing cell penetrating Alphabodies (CPABs) that have the potential to modulate intracellular PPIs, and has generated data demonstrating that CPABs are able to enter cells, bind to disease targets and can generate biological effects at low concentrations. CPABs have been designed to tackle the significant proportion of all known human disease targets that are located inside cells and cannot be addressed by either small chemical drugs or biologics. These targets belong to the most interesting class of potential drug targets, namely intracellular protein-protein interactions (PPIs), which are involved in important disease processes, such as those causing cancer, CNS, inflammation or metabolic diseases.
Therapeutic area: Cancer - Oncology - CNS diseases - Inflammatory diseases - Metabolic diseases
